Merck & Co. (MRK) is Reiterated by Deutsche Bank to Hold, Raises Price Target to $ 59

Merck & Co. (MRK) was Reiterated by Deutsche Bank to “Hold” according to the research note released today. The brokerage firm has raised the Price Target to $ 59 from a previous price target of $58 . Deutsche Bank advised their investors in a research report released on Aug 8, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Merck & Co. opened for trading at $62.51 and hit $64 on the upside on Friday, eventually ending the session at $63.86, with a gain of 10.41% or 6.02 points. The heightened volatility saw the trading volume jump to 7,28,75,999 shares. Company has a market cap of $176,766 M.

Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.

In a different news, on Aug 5, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 392,000 shares at $61.95 per share price. According to the SEC, on Jul 5, 2016, Weir Mirian M Graddick (Exe V-P, HR) sold 45,000 shares at $57.96 per share price. On Jul 1, 2016, Adam H Schechter (EVP & Pres-Global Human Health) sold 50,000 shares at $57.69 per share price, according to the Form-4 filing with the securities and exchange commission.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Merck & Co.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.